MedTrace Logo

Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2 ) Advanced/Metastatic Breast Cancer in the Arabian Gulf Region

NCT04916509 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 258

Last updated 2023-06-06

No results posted yet for this study

Summary

retrospective non-interventional study (NIS) that aims to describe the demographics, clinical characteristics, clinical outcomes, and treatment patterns, among patients receiving palbociclib for the treatment of HR+/HER2- metastatic/locally advanced breast cancer (BC)

Conditions

  • Breast Neoplasms

Interventions

DRUG

Palbociclib plus an aromatase inhibitor

Palbociclib plus an aromatase inhibitor therapy

DRUG

Palbociclib plus fulvestrant

Palbociclib plus fulvestrant

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

  • Meteb Al-Foheidi · King Abdul-Aziz Medical City, National Guard Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-13
Primary Completion
2022-12-27
Completion
2022-12-27

Countries

  • Qatar
  • Saudi Arabia
  • United Arab Emirates

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04916509 on ClinicalTrials.gov